Affordable Access

Publisher Website

Treating low HDL—From bench to bedside

Authors
Publisher
Elsevier Inc.
Publication Date
Volume
37
Issue
8
Identifiers
DOI: 10.1016/j.clinbiochem.2004.04.005
Keywords
  • High-Density Lipoproteins
  • Reverse Cholesterol Transport
  • Coronary Heart Disease
  • Oxidation
  • Inflammation
  • Thrombosis
  • Endothelial Function
  • Drugs
  • Therapeutics
Disciplines
  • Biology
  • Medicine

Abstract

Abstract The inverse relationship between the plasma high-density lipoprotein cholesterol (HDL-C) and the risk of coronary heart disease (CHD) is well recognized in the general population. However, the development of effective therapeutics targeting HDL continues to be challenging, which is due in part to the heterogeneity of its structure and composition and the complexity of its metabolism. In this paper, we review a number of recent advances in our understanding of HDL metabolism and its role in atherogenesis. We discuss the HDL-C raising effect of a selected number of currently available lipid-modifying drugs and on a selected number of novel HDL-targeted therapeutic strategies under development.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

Treating low HDL--from bench to bedside.

on Clinical Biochemistry August 2004

From bench to bedside.

on Michigan medicine 2008

"From bedside to bench".

on Journal of the American Colleg... Mar 03, 2004

From bench to bedside.

on Newsweek Jun 15, 2009
More articles like this..